Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

PatientsLikeMe launches 'virtual trial' in ALS

Partners with The Duke ALS Clinic on study of the Soy Peptide Lunasin

Virtual trial pharma PatientsLikeMe

PatientsLikeMe has started a small-scale 'virtual trial' to evaluate the potential of a peptide to reverse the symptoms of degenerative motor disorder ALS.

The online community is working with The Duke ALS Clinical in the US on the study, which will involve 50 patients with amyotrophic lateral sclerosis, known as motor neurone disease or Lou Gehrig's Disease.

The trial will test whether Lunasin, a peptide found in soy and some cereal grains, can help reverse ALS, following a review that found it might have beneficial effects. It's a particularly apt programme to be taken on by PatientsLikeMe as when the community was set up in 2005 it was initially as a website for ALS patients to share their experiences.

The Lunasin Virtual Trial (or, virtually virtual trial) is the first study of the supplement in ALS patients, and will see participants make three in-person visits to the Duke ALS clinic to measure the supplement's impact over the course of the year-long study.

They will also complete virtual check-ins as members of PatientsLikeMe every 30 days to update their weight and complete an evaluation of their Lunasin regimen as well as completing the ALS Functional Rating Scale, a patient-reported outcome tool. 

The trial's protocol has been published on Duke's ALS Reversals website and Duke ALS clinic director Richard Bedlack said that, in addition to its open approach, the work aims to eliminate many of the frustrations patients say are inherent in traditional clinical trials.

“There are no placebos, and we made the inclusion criteria very broad so that even ALS patients who can't qualify for other studies due to their long disease duration or use of a ventilator can qualify,” he said.

Attempts to pursue virtual trials within pharma have had mixed success to date, with Pfizer's pioneering efforts in managing study participation electronically ultimately abandoned in 2012. More recently, however, a Sanofi-backed consortium said in June this year that its VERKKO remote online phase IV clinical trial in diabetes had been a success.


11th November 2016

From: Research



Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...